Anurag Relan
Pharming Technologies BV · VP Clinical Research & Medical Affairs at Pharming · Pharming Group N.V.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anurag Relan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:24 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04912141 · Prevention of Acute Kidney Injury in Patients With NSTEMIPharming Technologies B.V. · terminated · Non-ST Elevation Myocardial Infarction (NSTEMI) · study director
- N/ANCT03697187 · Patient Registry to Evaluate the Real-world Safety of Ruconest®Pharming Technologies B.V. · completed · Hereditary Angioedema · study director
- N/ANCT01397864 · C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) AttacksPharming Technologies B.V. · completed · Hereditary Angioedema · study director
- Ph2NCT01359969 · Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) PatientsPharming Technologies B.V. · completed · Hereditary Angioedema · study director
- Ph2/Ph3NCT00225147 · Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaPharming Technologies B.V. · completed · Hereditary Angioedema, Angioneurotic Edema · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:24 UTC. The ranking covers the 200 most relevant of 19 PubMed records, and a shared surname and initials can bring in a namesake. All 19 on PubMed
- Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema.J Allergy Clin Immunol · 2010184 citationsRCR 6.4
- 114 citationsRCR 11.2
- Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial.Ann Allergy Asthma Immunol · 201471 citationsRCR 2.9
- Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk.Allergy · 201563 citationsRCR 2.5
- 51 citationsRCR 2.3
- Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study.Clin Exp Allergy · 201245 citationsRCR 1.9
- Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study.Ann Allergy Asthma Immunol · 201341 citationsRCR 1.6
- Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks.J Allergy Clin Immunol Pract · 201533 citationsRCR 1.4
- Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedema.BioDrugs · 201231 citationsRCR 1.1
- Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children.Pediatr Allergy Immunol · 201927 citationsRCR 1.7